In The News

Meet The Attys Arguing Supreme Court Biosimilars Battle


21 Apr 2017
Reprinted with permission.

In the Law360 article “Meet The Attys Arguing Supreme Court Biosimilars Battle” Morrison & Foerster partner Deanne E. Maynard offers insight into her legal strategy regarding the Sandoz Inc. v Amgen Inc. argument, in which she’s representing Sandoz. The highly-contested case will determine how quickly competition emerges for many of the world’s best-selling drugs, and features opposite readings of the Biologics Price Competition and Innovation Act.

Read the article and full strategy.



Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.